viewZelira Therapeutics Ltd

Zelda Therapeutics achieves patient milestone in autism treatment cannabis study

Parents of more than 100 kids aged about 10 are reporting how the treatments affect the children’s behaviour.

Zelda Therapeutics Ltd - Zelda Therapeutics achieves patient milestone in autism treatment cannabis study
One hundred and three kids are now in the Philadelphia study

Zelda Therapeutics Ltd (ASX:ZLD, FRA:G1G, OTCMKTS:ZLDAF) has enrolled a milestone 100th patient in a behavioural study evaluating its medicinal cannabis treatment in children on the autism spectrum.

The observational study at Children’s Hospital of Philadelphia (CHOP) now has 103 enrolled patients whose parents are reporting on the behavioural outcomes of cannabis treatments delivered in the study.

Kids in Zelda’s study are aged about 10 years old, diagnosed with autism and range in autism levels from classifications of low to medium or high-level severity.

A number of cannabis treatments are being trialled, one being THC-only, the other CBD-only or combinations of both — with a variety of dosings being studied.

Parents of the children are observing their kids’ behaviour for the study and are finding improvements.

The extent of the improvements depends on the type of treatment and dosings a child is administered.

Zelda managing director Dr Richard Hopkins reported today: “We’re very encouraged by the preliminary analysis of the data from this observational study.

“Results show that treatments with a range of cannabis medicines were associated with improvements in several key behavioural markers that are prominent in children diagnosed with autism.

“This highlights the potential for medicinal cannabis to improve outcomes for autistic children.”

Hopkins flagged the company believes its study is the first to report what he called “differences in autism severity based on responses to medicinal cannabis treatments.”

He said: “The ability to stratify patients according to various clinical criteria could help us better predict whether patients will be more likely to benefit from medicinal cannabis treatments.

“While these initial findings are encouraging, we need to be cautious interpreting the results from observational studies such as ours, where parent-reported data is used and where there is limited baseline information available prior to treatment, which can result in significant bias.”

To address the potential for bias that affects reported outcomes, Zelda hopes to design a randomised blinded trial of children with autism spectrum disorder later this year.

Hopkins told the market the company was well placed to be an early mover on medicinal cannabis as the pharmaceutical subsector was more regulated and prescription product requirements became more demanding clinically.

Quick facts: Zelira Therapeutics Ltd

Price: 0.076 AUD

Market: ASX
Market Cap: $90.08 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...


Zelira Therapeutics and Emyria team up for 'disruptive' autism spectrum...

Zelira Therapeutics Ltd's (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) Richard Hopkins and Emyria Ltd's (ASX:EMD) Michael Winlo speak to Proactive's Andrew Scott after announcing they've entered into an agreement to conduct an observational trial for patients diagnosed with autism spectrum disorder (ASD)...

2 weeks, 3 days ago

2 min read